Kevin is an established Corporate Strategy, Business Development (IN-/OUT-licensing), M&A (acquisitions/divestitures) professional with 30 years of biopharmaceuticals experience. His responsibilities include close leadership of the US and EU BD&L teams, Global Strategic Investments/Post Investment Management (PIM), and Global Alliance Management. Kevin is a Simcere Executive Management Team member and also a member of Simcere Innovation’s Senior Management Team.

Prior to joining Simcere, Kevin was Global Head of BD&L-External Alliances at Alcon, a division of Novartis. Prior to this, he served for 9 years in various leadership roles in BD at Merck, having previously led CNS drug target validation for 12 years at Merck, Sharp & Dohme. Notable achievements in his R&D career include the identification and validation of the CGRP receptor, work that he extensively published and that formed the concept underpinning the new class of anti-migraine agents, both biologics and small molecules.

Kevin holds a Ph.D. degree in Neuropathology from the University of Cambridge, and a B.Sc in Immunology from King’s College London. Kevin’s office is located at Simcere Innovation in Cambridge, MA.